Medicine
Adstiladrin 300000000000 VP/mL injectable suspension
Adstiladrin 300000000000 VP/mL injectable suspension is a prescription medicine containing Nadofaragene firadenovec for intravesical use, marketed by Ferring Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Upon receipt, cartons of ADSTILADRIN can be stored as indicated below: In a…
Key facts
- Active ingredient (INN)
- Nadofaragene firadenovec
- Brand
- Adstiladrin
- Strength
- 300000000000 VP/mL
- Dosage form
- Injectable suspension
- Route
- Intravesical
- Packs
- 4 vials, 20 mL
- Marketing authorisation holder
- Ferring Pharmaceuticals
- Manufacturer
- Ferring Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Upon receipt, cartons of ADSTILADRIN can be stored as indicated below: In a freezer ≤ -60°C (≤ -76°F) until expiry date printed on the carton. ADSTILADRIN is shipped frozen at ≤ -60°C (≤ -76°F) in an insulated shipping box that will maintain the required temperature for a minimum of 72 hours after being sealed.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01XL10 Nadofaragene firadenovec
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 5 September 2023
- Identifiers
- RxCUI 2644440, 2644445DailyMed set ID 5ca20ed4-da4f-463c-ac2a-ccd6ab3774faNDC 55566-1050Application BLA125700
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 4 vial in 1 carton / 20 mL in 1 vial | 55566-1050-1 | Ferring Pharmaceuticals | 5 September 2023 |
| 20 mL in 1 vial | 55566-1050-2 | Ferring Pharmaceuticals | 13 October 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Nadofaragene firadenovec is a prescription medicine indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. MedsAcross supplies Nadofaragene firadenovec for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Nadofaragene firadenovecFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- ADSTILADRIN prescribing information (Ferring Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Adstiladrin: European public assessment report (EPAR) · European Medicines Agency
Need Adstiladrin 300000000000 VP/mL injectable suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.